SAN FRANCISCO – Amid the flurry of deals and financings news to hit on the first day of the J.P. Morgan Healthcare Conference, Jazz Pharmaceuticals plc disclosed the latest acquisition to its growing pipeline, with the licensing of a Phase III-ready narcolepsy drug, and its goal of topping the $1 billion revenue mark in 2014.